control
crystal
crystallization
crystals
delivery
development
drug
engineering
equipment
high
inhaled
manufacture
manufacturing
medicines
oxford
particle
particles
pharmaceutical
power
process
processing
product
products
proprietary
prosonix
respiratory
scale
science
size
technologies
technology
ultrasonic
ultrasound
used
using
| Prosonix and UCB Extend Co-Development Agreement |
 |
 |
 |
| Tuesday, 19 December 2006 12:54 | ||||
|
Prosonix Ltd (Oxford UK) and UCB SA (Braine l’Alleud, Belgium), are pleased to announce the extension of their Co-Development and Licensing Agreement for the utilization of Prosonix’ proprietary sonocrystallization technology across a range of its pharmaceutical products.
             |
||||
| Last Updated on Sunday, 18 January 2009 19:41 |
Navigation
Latest News
03 Feb 2012 - Geoff Down appointed as Chief Medical Officer
Prosonix Appoints Respiratory Drug Development Expert Dr Geoff Down as Chief Medical Officer Prosonix (Oxford, UK), an emerging pharmaceutical company developing a portfolio of enhanced respiratory...
Prosonix Appoints Respiratory Drug Development Expert Dr Geoff Down as Chief Medical Officer Prosonix (Oxford, UK), an emerging pharmaceutical company developing a portfolio of enhanced respiratory...
More in: Latest
